[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-thromboembolism-vte\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-thromboembolism-vte":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,44,69,103,116,158,184,206,232,258,284,306,340,363,395,425,454,477,509,544,574,602,627,656],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054279","phase-3-regn7508-versus-apixaban-and-enoxaparin-for-thromboprophylaxis-after-total-knee-arthroplasty-in-adults-100054279",false,"NCT07015905","REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)","ROXI-APEX","Key Inclusion Criteria:\n\n1. Is undergoing a primary elective unilateral TKA\n2. Is in good health based on laboratory safety testing as described in the protocol\n3. Body weight ≤130 kg at screening visit as described in the protocol\n\nKey Exclusion Criteria:\n\n1. Any condition that, as assessed by the investigator, may confound the results of the study or pose an additional risk to the participant by study participation\n2. History of bleeding in the 6 months prior to randomization requiring hospitalization or transfusion as described in the protocol\n3. History of thromboembolic disease or thrombophilia\n4. History of major surgery, including brain, spinal, or ocular, or major trauma within approximately the past 6 months prior to randomization\n5. Has an estimated Glomerular Filtration Rate (GFR) of \\\u003C30 mL\u002Fmin\u002F1.73 m2 at the screening visit as described in the protocol\n\nNote: Other protocol-defined Inclusion\u002F Exclusion Criteria apply","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is researching an experimental drug called REGN7508 (called \"study drug\"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery.\n\nThe aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)",[27],"Venous Thromboembolism (VTE)",[29,30],"Unilateral Total Knee Arthroplasty (TKA)","Factor XI (FXI)","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2025-06-25",{"date":39,"type":21},"2027-05-12",{"name":41,"class":42},"Regeneron Pharmaceuticals","INDUSTRY",46,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100054069","phase-3-venous-thromboembolism-vte-prophylaxis-with-regn7508-and-regn9933-in-adult-and-adolescent-participants-with-a-peripherally-inserted-central-catheter-picc-100054069","NCT07697599","Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)","A Master Protocol for a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, for Prophylaxis of Venous Thromboembolism in Participants With a Peripherally Inserted Central Catheter (PICC) (ROXI-PEAK)","ROXI-PEAK","Key Inclusion Criteria:\n\n1. Is undergoing PICC placement for Intravenous (IV) administration of clinically indicated medications, including chemotherapy, antibiotics, TPN, and\u002For other indications as described in the protocol\n2. Has Eastern Cooperative Oncology Group Performance (ECOG) Status ≤3 or equivalent functional status as described in the protocol\n3. Has International Normalization Ratio (INR) and aPTT values no more than 25% above the upper limit as described in the protocol\n4. Weighs at least 40 kg during the screening period\n\nKey Exclusion Criteria:\n\n1. Has a history of prior venous thrombosis in the arm and\u002For ipsilateral thoracic central veins in which the PICC is to be placed\n2. Has acute leukemia, myelodysplastic syndrome, or primary and secondary myelofibrosis\n3. Has unresected luminal gastrointestinal (GI) (including esophageal) or unresected genitourinary (GU) malignancy\n4. Has current or history of known brain tumors or brain metastases\n5. Has any major cardiovascular event within approximately the past 30 days prior to study administration\n6. Pre-existing central venous catheter or indwelling spinal or epidural catheter during the screening period\n\nNote: Other Protocol Defined Inclusion\u002F Exclusion Criteria Apply","15 Years",{"count":54,"type":21},1908,[24],"This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called \"study drugs\"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted Central Catheter \\[PICC\\]). Patients with PICCs have a higher risk of getting blood clots which can block the veins (this is called Venous Thromboembolism \\[VTE\\]) and lead to serious health problems or be life threatening.\n\nThe aim of the study is to see how well REGN7508 and REGN9933 prevent blood clots compared to placebo after PICC placement and to see if these medications cause certain types of bleeding.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drugs\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)\n* If the study drugs affect the ability of the blood to clot normally",[27],[59,60],"Peripherally Inserted Central Catheter (PICC)","Blood clots","NOT_YET_RECRUITING","2026-07-06",{"date":34,"type":35},{"date":65,"type":21},"2026-08-20",{"date":67,"type":21},"2029-09-21",{"name":41,"class":42},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100642274","decision-aid-for-anticoagulation-duration-after-unprovoked-venous-thromboembolism-100642274","NCT07659106","Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism","Enabling and Engaging Patients to Decide Indefinite Versus Short-Term Anticoagulation for Venous Thromboembolism (DECIDE-VTE)","DECIDE-VTE","Inclusion Criteria:\n\n* Age 18 years or older\n* First episode of objectively confirmed unprovoked or weakly provoked venous thromboembolism (VTE)\n* Objectively confirmed proximal deep vein thrombosis and\u002For segmental or greater pulmonary embolism\n* Completed at least 3 months of therapeutic anticoagulation and currently receiving anticoagulation\n* Enrollment within 12 months of diagnosis of the index\u002Fqualifying VTE event\n* Able to provide written informed consent\n* Able to participate in shared decision-making in English or French\n\nExclusion Criteria:\n\n* Recurrent unprovoked or weakly provoked VTE I(i.e. multiple unprovoked\u002Fweakly provoked VTE)\n* Index\u002Fqualifying VTE is a strongly provoked VTE (e.g., associated with major surgery, major trauma, plaster cast immobilization, or prolonged bed rest)\n* Index\u002Fqualifying VTE associated with a persistent strong provoking risk factor (e.g., active cancer or ongoing immobility)\n* Women at very low recurrence risk (HERDOO2 score 0-1)\n* High bleeding risk such that anticoagulation should be discontinued\n* Requirement for long-term anticoagulation for another indication (e.g., atrial fibrillation)\n* Prior dedicated long-term anticoagulation Decision Visit regarding anticoagulation duration",{"count":78,"type":21},850,[80],"NA","Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common condition that is typically treated with blood thinners (anticoagulants). After completing at least 3 months of treatment for a first unprovoked or weakly provoked VTE, patients and clinicians must decide whether to stop anticoagulation or continue treatment for a longer period. Continuing anticoagulation reduces the risk of another blood clot but increases the risk of bleeding. Because both options involve important benefits and risks, this decision should reflect the patient's values and preferences.\n\nThe DECIDE-VTE study will evaluate whether a patient decision aid can improve decision-making for patients facing this choice. The decision aid provides evidence-based information about the risks and benefits of continuing versus stopping anticoagulation and includes a values clarification exercise to help patients identify what matters most to them.\n\nThis multicentre batched stepped-wedge cluster randomized trial will be conducted in 12 thrombosis clinics across Canada. Clinics will transition from usual care to implementation of the patient decision aid according to a randomized schedule. The primary outcome is decisional conflict immediately following the anticoagulation decision visit, measured using the Decisional Conflict Scale. Secondary outcomes include patient knowledge, treatment decisions, decisional regret, concordance with the chosen treatment strategy, recurrent venous thromboembolism, major bleeding, all-cause mortality, and implementation outcomes.",[27,83,84],"Deep Vein Thrombosis (DVT)","Pulmonary Embolism",[86,87,88,89,90,91],"Anticoagulation","Patient Decision Aid","Shared Decision Making","Extended Anticoagulation","Decisional Conflict","Stepped-Wedge Cluster Randomized Trial","2026-06-19",{"date":94,"type":35},"2026-06-24",{"date":96,"type":21},"2026-09",{"date":98,"type":21},"2029-03",{"name":100,"class":101},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",5,{"id":104,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":25,"conditions":107,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":114,"locationsCount":115},"100594166",{"count":20,"type":21},[24],[27],[29,30],"2026-06-15",{"date":111,"type":35},"2026-06-17",{"date":37,"type":35},{"date":39,"type":21},{"name":41,"class":42},45,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":138,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100603978","early-exercise-based-rehabilitation-in-patients-hospitalized-for-acute-pulmonary-embolism-100603978","NCT07143539","Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism","Early Exercise-based Rehabilitation in High-risk Patients Hospitalized for Acute Pulmonary Embolism: a Pragmatic Multicenter Randomized Partially Blinded Superiority Trial","RehabPE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days\n3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension)\n2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)\n3. Recently completed (i.e., \\\u003C6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication\n4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)\n5. Contraindication to anticoagulation\n6. Life expectancy \\\u003C1 year based on the treating physician's clinical judgement\n7. Known pregnancy\n8. Inability to speak German or French\n9. Participation in another study that prohibits concurrent participation in RehabPE\n10. Unable to provide informed consent (e.g., due to dementia)\n11. Unwilling to provide informed consent\n12. Prior enrollment in this study",{"count":125,"type":21},160,[80],"Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects.\n\nThe study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management.\n\nOver 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work \u002F usual daily activities will be monitored and compared between groups.",[27,129,130,131,132,133,134,135,136,137],"Exercise Therapy","Quality of Life (QOL)","Anxiety Depression","Humans","Exercise Tolerance","Rehabilitation Exercise","Dyspnea","Functional Status","Pulmonary Embolism (Diagnosis)",[139,140,141,142,143,144,145,146,147],"pulmonary embolism","deep vein thrombosis","excercise-based rehabilitation","post-PE syndrome","health-related quality of life","anxiety","depression","dyspnea","impact of early excercise-based rehabilitation","2026-06-11",{"date":150,"type":35},"2026-06-12",{"date":152,"type":35},"2025-12-17",{"date":154,"type":21},"2028-06",{"name":156,"class":101},"Insel Gruppe AG, University Hospital Bern",6,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":166,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100581062","phase-4-prevention-of-postpartum-venous-thromboembolism-in-women-at-intermediate-risk-100581062","NCT06845423","Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk. An Open-label, Randomized, Controlled Trial Comparing Two Strategies With or Without Pharmacological Thromboprophylaxis","MUM-VTE","Inclusion Criteria:\n\n* Women at intermediate risk of VTE during post-partum= with a 3% or more risk of VTE based on a validated prediction model\\* or International guidelines (ACCP 2012).\n* Age over 18 years\n* Delivery between 6 hours and \\\u003C 36 hours\n* Written informed consent\n\n  * Definition: Intermediate risk is defined as ≥ 3%, based on risk prediction model developed by Sultan et al taking in account: smoking, varicose veins, obesity, comorbidities, diabetes, pre-eclampsia, post-partum hemorrhage, postpartum infection, emergency or elective section or following ACCP guidelines: one major risk factor or two minor risk factors.\n\nExclusion Criteria:\n\n* Previous personal history of VTE\n* LMWH started during antenatal period\n* Need for anticoagulation at curative dose\n* Contraindication to LMWH (previous heparin induced thrombopenia, hemostatic impairment, known severe renal insufficiency)\n* Women who received more than two doses of LMWH since delivery\n* Unable or refusal to give informed consent\n* Aspirin at a daily dose 100 mg or dual antiplatelet therapy\n* Previous inclusion in Mum-VTE study\n* Concomitant participation in another therapeutic study","FEMALE",{"count":168,"type":21},2400,[170],"PHASE4","Venous thromboembolism (VTE) is currently the second cause of death in women of reproductive age worldwide. The incidence of VTE during pregnancy is 1.2 to 1.4\u002F1000 women, half of VTE occurring during postpartum and as PE in majority of cases, accounting for 8.8% of maternal deaths.\n\nMajority of postpartum VTE occurs in women with one or more moderate risk factors (obesity, caesarean section, postpartum hemorrhage). For these women at intermediate risk, the efficacy and safety of thromboprophylaxis have not been assessed yet during postpartum and international guidelines for pharmacological thromboprophylaxis, based on data extrapolated from other populations, observational studies and small clinical trials are inconsistent across countries.\n\nWe designed an open-label, randomized, controlled trial, aiming to demonstrate the superiority of a pharmacological thromboprophylaxis strategy with LMWH (LMWH type chosen according to physician \u002F patient's preference) during 6 weeks after delivery (the 6-weeks follow-up visit being matched with usual care) in women at intermediate risk, over no pharmacological thromboprophylaxis.",[27,173],"Post Partum Women","2026-06-09",{"date":176,"type":35},"2026-06-10",{"date":178,"type":35},"2025-05-16",{"date":180,"type":21},"2028-08-16",{"name":182,"class":101},"University Hospital, Brest",18,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":191,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100520536","molecular-imaging-of-active-venous-thrombus-with-positron-emission-tomography-pet-100520536","NCT06057844","Molecular Imaging of Active Venous Thrombus With Positron Emission Tomography (PET)","THROMPET","Inclusion Criteria:\n\nMajor patient (≥18 years), voluntary blood donor, with no notable medical history altering coagulation (i.e. known thrombophilia, active cancer), no chronic pathology, no current treatment.\n\nExclusion Criteria:\n\nMinor patient (\\\u003C18 years); known chronic pathology; long-term treatment including anti-platelet aggregation therapy or anticoagulant treatment, refusal to participate.",true,{"count":193,"type":21},10,[80],"Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and\u002For pulmonary embolism (PE), is a major public health issue. VTE is the third most common acute cardiovascular pathology, after myocardial infarction and stroke.\n\nDiagnostic accuracy is essential in the case of VTE, in order to select patients for whom anticoagulant treatment is necessary, and to avoid long-term treatment of patients who will derive no benefit from it.\n\nThe management of patients with suspected PE is based on diagnostic strategies that use either ventilation-perfusion planar lung scintigraphy or thoracic angioscanner imaging as the cornerstone. These 2 techniques correspond to what might be termed \"negative\" imaging, i.e. visualization of the vascular repercussions downstream of an obstruction, whatever its nature.\n\nA research prospect in the field of VTE diagnosis is the direct marking of the various elements of the active venous thrombus, which could correspond to \"positive\" thrombus imaging.\n\nNumerous studies have already investigated the role of molecular imaging in the diagnosis of VTE, especially in the diagnosis of DVT. However, these studies used conventional scintigraphy to evaluate these tracers, a technique lacking in sensitivity and with insufficient spatial resolution.\n\nNuclear medicine and molecular imaging have undergone a technological revolution since the early 2000s, with the development of positron emission tomography (PET). The technical advantages of PET over conventional scintigraphy include greater sensitivity and higher spatial resolution (4 mm for PET vs. 12 mm for conventional scintigraphy), which may have been the limiting factor in studies already carried out.\n\nThe aim of this project is to develop a new radiopharmaceutical for use in PET scans, a biomarker of active venous thrombus, with a view to improving the diagnosis of MVTE and hence patient management.",[27],"2026-06-05",{"date":199,"type":35},"2026-06-08",{"date":201,"type":35},"2024-02-27",{"date":203,"type":21},"2026-08-28",{"name":182,"class":101},1,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":231},"100630871","phase-3-treatment-and-secondary-prevention-of-venous-thromboembolism-vte-in-adult-participants-with-solid-and-hematologic-cancers-100630871","NCT07493304","Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers","A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants With Solid and Hematologic Cancers (ROXI-CAT-II)","ROXI-CAT-II","Key Inclusion Criteria:\n\n1. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 at the time of screening and day 1 prior to first dose of study intervention\n2. In Part 1 participants with cancer and Part 2 participants: Histologically confirmed diagnosis of malignant solid or select hematologic tumor (other than basal-cell or squamous-cell carcinoma of the skin alone) as described in the protocol\n3. Part 1 additional criteria:\n\n   1. Has newly diagnosed symptomatic lower extremity DVT or incidentally-detected proximal lower extremity DVT (eg, popliteal or femoral) within 5 days (120 hours) of randomization (with imaging confirmation)\n   2. Anticoagulation therapy with a therapeutic dose of a Direct Oral Anticoagulant (DOAC) for at least 3 months is indicated for the newly diagnosed proximal lower extremity DVT\n4. Part 2 additional criteria:\n\n   1. Newly diagnosed VTE within 5 days (120 hours) of randomization (with imaging confirmation) as described in the protocol\n   2. Anticoagulation therapy with a therapeutic dose of a DOAC for at least 6 months is indicated for newly diagnosed VTE\n\nKey Exclusion Criteria:\n\n1. Is at high risk of intracranial bleeding in the opinion of the investigator\n2. Known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)\n3. Contraindication to anticoagulation in the opinion of the investigator\n4. Life expectancy of \\\u003C 6 months\n5. Part 1 participants with cancer and Part 2 additional exclusion criteria:\n\n   1. Has acute leukemia or myelodysplastic syndrome\n   2. Has primary brain tumor\n   3. Has brain metastases as described in the protocol\n6. Part 1 additional exclusion criteria:\n\n   1. Has a symptomatic PE\n   2. Has an asymptomatic (incidentally-diagnosed) PE in a segmental or larger pulmonary artery\n7. Part 2 additional exclusion criteria: PE leading to hemodynamic instability as described in the protocol\n\nNote: Other Protocol Defined Inclusion\u002F Exclusion Criteria Apply",{"count":215,"type":21},1600,[24],"This study is researching an experimental drug called REGN7508 (called \"study drug\") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \\[DVT\\]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lungs (also called Pulmonary Embolism \\[PE\\]) (Part 2).\n\nThe aim of the study is to see how safe and effective the study drug is at treating and preventing further blood clots in participants with or without cancer (Part 1) or in participants with cancer (Part 2) compared with another treatment (apixaban).\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug\n* How much study drug is in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)",[27],[220,83,221,222],"Cancer-Associated Thrombosis (CAT)","Pulmonary Embolism (PE)","Cancer","2026-05-26",{"date":225,"type":35},"2026-05-29",{"date":227,"type":21},"2026-06-30",{"date":229,"type":21},"2031-07-08",{"name":41,"class":42},2,{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":239,"maxAge":18,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":205},"100564407","phase-3-collaborative-risk-stratified-investigation-in-thrombosis-prone-inpatients-with-critical-illness-anticoagulation-with-lmwh-in-teens-for-thromboprophylaxis-critical-teens-tp-100564407","NCT06628778","Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).","Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP)","Inclusion Criteria:\n\n* Admission Age between 12- 18 years of age\n* Within 24 hours of pediatric intensive care unit (PICU) admission for enrollment\n* Presence of a Central Venous Catheter\n* Presumed or confirmed infection or systemic inflammatory condition\n\nExclusion Criteria:\n\n* Active treatment for VTE or known VTE present prior to or on pediatric intensive care unit (PICU) admission\n* Current receipt of an antithrombotic agent excluding unfractionated heparin for vascular catheter patency\n* Active ISTH-defined clinically relevant bleeding\n* Surgery in the last 7-days\n* Major trauma within the last 7-days\n* Admission for management of congenital heart disease including perioperative management of critical congenital heart disease\n* Presence of coagulopathy including:\n* International normalized ratio (INR) 2.0 activated partial thromboplastin time (aPTT) 50 seconds Platelet count 50 x103\u002FmL\n* Creatinine clearance 30 ml\u002Fmin\u002F1.73 m2\n* Known hypersensitivity to heparin or pork products\n* Laboratory confirmed heparin induced thrombocytopenia\n* Current pregnancy or lactation,\n* Presence of an epidural catheter\n* Prior enrollment in the CRITICAL-Teens-TP Trial","12 Years",{"count":241,"type":21},802,[24],"Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.",[27],[246,247,248,249],"pediatric","adolescent","critical illness","thromboprophylaxis","2026-05-21",{"date":223,"type":35},{"date":253,"type":21},"2027-04-15",{"date":255,"type":21},"2035-04-15",{"name":257,"class":101},"Johns Hopkins All Children's Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":268,"phases":4,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100636023","3d-eit-for-diagnosis-and-monitoring-of-pulmonary-embolism-100636023","NCT07560293","3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism","Prospective Validation of Three-Dimensional Electrical Impedance Tomography for the Diagnosis, Risk Stratification, and Longitudinal Monitoring of Pulmonary Embolism","TIDE-PE","Inclusion Criteria:\n\n* Age 18 years or older\n* Body mass index (BMI) less than 50 kg\u002Fm²\n* Able to provide written informed consent\n* first episode of pulmonary embolism confirmed by CT pulmonary angiography (CTPA), with or without CT venography (CTV)\n\nExclusion Criteria:\n\n* Previous diagnosis of pulmonary embolism\n* Pregnancy\n* Thoracic deformity or chest wall abnormality preventing proper placement of the EIT electrode belt\n* Contraindications to EIT use, including implantable cardioverter-defibrillator, pacemaker, implanted pumps, or chest wounds limiting electrode placement\n* Concurrent participation in another interventional clinical study Hemodynamic instability requiring emergency intervention that precludes completion of the EIT examination (PE cohort only)\n* Any other condition judged by the investigator to make the participant unsuitable for study participation",{"count":267,"type":21},115,"OBSERVATIONAL","This prospective observational study aims to validate three-dimensional electrical impedance tomography (3D-EIT) as a non-invasive bedside tool for the diagnosis and longitudinal monitoring of pulmonary embolism (PE). The study will include a PE cohort and a control cohort without PE or venous thromboembolism (VTE). Using algorithms that separate ventilation and perfusion signals, 3D-EIT-derived indices, including the Matching Index (MI), Dead Space Index (DI), and Shunt Index (SI), will be quantified. The diagnostic performance of MI and DI will be evaluated against computed tomography pulmonary angiography (CTPA), and their associations with PE severity, risk stratification, and treatment response will be explored. This study is expected to support the clinical translation of 3D-EIT as a radiation-free bedside functional imaging tool for PE management.",[137,27],[84,272,273,274,275],"Electrical Impedance Tomography","Three-dimensional Imaging","Lung Perfusion","Ventilation-Perfusion Mismatch","2026-04-24",{"date":278,"type":35},"2026-05-01",{"date":278,"type":21},{"date":281,"type":21},"2028-05-01",{"name":283,"class":101},"Beijing Tsinghua Chang Gung Hospital",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":293,"studyType":268,"phases":4,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":205},"100626773","study-of-risk-factors-and-prediction-of-blood-clots-after-lung-cancer-surgery-100626773","NCT07439991","Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery","Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients undergoing surgical resection for lung cancer\n3. Postoperative hospital stay ≥ 48 hours\n4. Availability of perioperative clinical, laboratory, and imaging data\n5. Willingness to provide informed consent and participate in 30-day follow-up\n\nExclusion Criteria:\n\n1. Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery\n2. Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks\n3. Severe coagulation disorders or bleeding diseases\n4. Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection\n5. Concurrent major organ surgery (e.g., cardiac, liver surgery)\n6. Pregnancy or lactation\n7. Incomplete postoperative follow-up data",{"count":292,"type":21},900,"30 Days","The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is:\n\nWhich clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk?\n\nParticipants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.",[296,83,27],"Lung Cancer (Diagnosis)","2026-02-23",{"date":299,"type":35},"2026-02-27",{"date":301,"type":35},"2024-11-01",{"date":303,"type":21},"2029-11-30",{"name":305,"class":101},"The First Hospital of Jilin University",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":322,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":4},"100626199","phase-3-design-and-rationale-of-the-colt-study-100626199","NCT07432529","Design and Rationale of the COLT Study","Design and Rationale of the COLT Study: a Multicentre, Randomised, Double-blind, Placebo-controlled Trial of COLchicine as Adjunctive Therapy to Standard Anticoagulation in Acute Proximal Deep Vein Thrombosis of the Lower Limbs","COLT","Inclusion Criteria:\n\n1. Age ≥18 years at the time of screening.\n2. Objectively confirmed first, symptomatic acute proximal lower-limb deep vein thrombosis (DVT), involving the popliteal vein or more proximal veins, diagnosed within the previous 48 hours.\n3. Planned initiation of standard anticoagulation therapy, including:\n\n   * Low-molecular-weight heparin (LMWH) bridging to vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs),\n   * DOAC monotherapy according to local guidelines,\n   * Fondaparinux or other guideline-recommended regimens. Note: Standard anticoagulation regimens include dose reduction of apixaban or rivaroxaban at the sixth month, as per local practice.\n4. Ability and willingness to provide written informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. History of prior DVT in the same limb.\n2. Known contraindications to anticoagulation or anticipated inability to comply with study procedures.\n3. Current use of colchicine or clinical indication requiring colchicine therapy.\n4. Known hypersensitivity or allergy to colchicine.\n5. Severe hepatic impairment, defined as ALT or AST \\>3× upper limit of normal, or severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin).\n6. Active malignancy with an estimated life expectancy \\\u003C12 months.\n7. History of active or chronic gastrointestinal disease that may interfere with colchicine tolerance, including:\n\n   1. Inflammatory bowel disease (Crohn's disease or ulcerative colitis),\n   2. Collagenous colitis,\n   3. Irritable bowel syndrome,\n   4. Chronic or recurrent diarrhea.\n8. Recent (\\\u003C30 days) or ongoing use of systemic immunosuppressive therapy, including but not limited to corticosteroids, cyclosporine, or tumor necrosis factor-alpha inhibitors.\n9. Pregnancy or breastfeeding, or unwillingness to use effective contraception during the study period.\n10. Concomitant use of strong CYP3A4 inhibitors or P-glycoprotein inhibitors contraindicated with colchicine.\n11. Major bleeding event within the past 30 days or assessed as high bleeding risk by the investigator.\n12. Inability or unwillingness to provide informed consent or to comply with study procedures.",{"count":315,"type":21},940,[24],"Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep veins of the leg and can lead to long-term problems such as leg pain, swelling, and reduced quality of life. Standard treatment with blood-thinning medication lowers the risk of complications, but some patients still develop long-term damage to the veins. Inflammation is thought to play an important role in these complications.\n\nThis study will evaluate whether adding colchicine, an anti-inflammatory medication already used for other conditions, to standard anticoagulant therapy can improve outcomes in patients with acute DVT. Participants will be randomly assigned to receive either colchicine or a placebo, in addition to usual blood-thinning treatment, and will be followed for one year.\n\nThe main goal of the study is to determine whether colchicine reduces the risk of developing long-term vein problems after DVT. The study will also assess the risk of new blood clots, vein recovery, quality of life, and the safety of colchicine treatment.",[319,320,27,321],"Venous Thrombosis Deep (Limbs)","Post-thrombotic Syndrome","Venous Insufficiency",[323,324,325,326,327,328,329],"Deep vein thrombosis","Venous thromboembolism","Post-thrombotic syndrome","Colchicine","Anticoagulation therapy","Randomized controlled trial","Inflammation","2026-02-21",{"date":332,"type":35},"2026-02-25",{"date":334,"type":21},"2026-06-01",{"date":336,"type":21},"2027-06-01",{"name":338,"class":339},"Azienda Sanitaria Locale ASL 6, Livorno","OTHER_GOV",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":166,"minAge":18,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":205},"100603722","phase-3-short-term-low-dose-low-molecular-weight-heparin-to-prevent-postpartum-thrombosis-100603722","NCT07140211","Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis: a Pragmatic, Multi-center, Open-label Randomized Controlled Study","SHINE","Inclusion Criteria: postpartum women after delivery AND ≥1 major risk factor \u002F ≥2 minor risk factors:\n\n* Major risk factors: Emergency cesarean section ; Pre-pregnancy BMI ≥35kg\u002Fm2 ; Known low-risk thrombophilia (heterozygous factor V Leiden; heterozygous G20210 prothrombin mutation) ; Pre-eclampsia ; Pre-term delivery ; Peripartum systemic infection ; Intra-uterine growth restriction ; Pregnancy loss\n* Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg\u002Fm2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility\n\nExclusion Criteria:\n\n* ≥2 doses of postpartum LMWH\n* Any indication for therapeutic anticoagulation\n* A high-risk of postpartum VTE\n* An increased bleeding risk\n* A contra-indication to heparin",{"count":349,"type":21},9200,[24],"The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are:\n\n* compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery?\n* compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.",[27,353],"Postpartum","2026-02-12",{"date":356,"type":35},"2026-02-17",{"date":358,"type":35},"2025-10-15",{"date":360,"type":21},"2030-08",{"name":362,"class":101},"Marc Blondon",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":268,"phases":4,"briefSummary":373,"conditions":374,"keywords":383,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":205},"100624164","duke-virtual-integrated-workflow-100624164","NCT07406074","Duke Virtual IntEgrated Workflow","DUH Innovation Units","Duke VIEW","Inclusion Criteria:\n\n* Admission to the hospital on one of six clinical units\n\nExclusion Criteria:\n\n* Less than 18 years old",{"count":372,"type":21},10000,"This quality improvement initiative aims to evaluate the implementation, utilization, and impact of virtual care technologies and workflows being implemented at Duke University Health System (DUHS). This project is embedded within operational workflows and is designed to inform strategic decision-making and resource allocation. The evaluation will focus on key performance indicators (KPIs) relevant to hospital operations and patient outcomes, including but not limited to: Length of Stay, Readmission Rates, Patient Satisfaction Scores, and Other Quality and Safety Metrics. These KPIs will be evaluated across three clinical units at Duke University Hospital, in which virtual care technologies are being implemented. These will be compared to three control units of similar characteristics. Differences in KPIs will be examined across all units over 12 months.",[375,376,377,378,379,27,380,381,382],"Falls Injury","Readmission Rates","CLABSI - Central Line Associated Bloodstream Infection","Catheter Associated Urinary Tract Infection","Hospital Acquired Pressure Injury","Nurses","Satisfaction, Patient","Length of Stay",[384,385,386],"Virtual Care","Nursing","Inpatient","2026-02-09",{"date":354,"type":35},{"date":390,"type":21},"2026-02-04",{"date":392,"type":21},"2027-02-03",{"name":394,"class":101},"Duke University",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":17,"minAge":403,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100588129","delivery-and-implementation-of-a-randomised-crossover-trial-on-thrombosis-100588129","NCT06937372","Delivery and Implementation of a Randomised Crossover Trial on Thrombosis","Delivery and Implementation of a Randomised Cluster Crossover Trial on Thrombosis","DIRECT","Inclusion Criteria:\n\n* Adults from 60 to 150 years sustaining fragility hip fracture identified by their entry into UK hip registries.\n\nExclusion Criteria:\n\n* Individuals who do not meet the eligibility criteria to be enrolled in the NHFD and SHFA registries Hip fracture individuals above 150 years of age.","60 Years","120 Years",{"count":406,"type":21},21194,[80],"What is the Study About? The DIRECT study (Delivery and Implementation of a Randomised Crossover Trial on Thrombosis) is a large research project investigating the best way to prevent blood clots (thrombosis) in people who break their hip. The study will compare two common treatments: aspirin (a tablet) and low molecular weight heparin (LMWH, an injection).\n\nEvery year, thousands of people in the UK suffer a hip fracture, which often requires surgery and hospital care. After a hip fracture, patients are at risk of developing serious blood clots in their legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE), which can be life-threatening. Currently, doctors prescribe different medications to prevent these clots, but there is uncertainty about which treatment is best for people with hip fractures.\n\nWhy is This Study Needed? Blood clot prevention is vital for hip fracture patients, but the current recommended treatment (LMWH) involves daily injections for 28 days, which some patients find uncomfortable and difficult to manage at home. Aspirin, a tablet taken by mouth, is a much simpler alternative, but there is not enough evidence to confirm whether it is as effective and safe as LMWH in this group of patients.\n\nThe DIRECT study will help doctors and the NHS understand whether aspirin could be a safe and cost-effective alternative to LMWH. If aspirin is found to be just as effective, it could make treatment easier for patients and save millions of pounds for the NHS.\n\nHow Will the Study Work? The study will involve 96 hospitals across the UK and will include over 21,000 patients aged 60 and older who have broken their hip. Hospitals will be randomly assigned to use either aspirin or LMWH as their standard treatment for a set period. After this, they will switch to the other treatment. This approach allows researchers to compare the two treatments fairly.\n\nAll data will be collected from national NHS databases, which routinely record patient care and outcomes. This means patients will not need to do anything extra or attend additional follow-ups.\n\nWhat Are the Expected Benefits?\n\nThis study will provide clear evidence on which treatment is better for preventing blood clots while minimising risks like bleeding. If aspirin is shown to be as effective as LMWH, it could:\n\n* Reduce the need for daily injections, making treatment more comfortable for patients.\n* Lower NHS costs, as aspirin is much cheaper than LMWH.\n* Provide a simple, widely available treatment option for older adults with hip fractures.\n\nHow Will Patient Data Be Protected? The study will use anonymised patient data from NHS records. This means that all personal details will be kept confidential and protected according to strict NHS and research regulations. Patients who do not want their data to be used can opt out via NHS data-sharing policies.\n\nSummary The DIRECT study is an important project that will help improve care for hip fracture patients by determining whether aspirin can be a safe and effective alternative to injections for preventing blood clots. The results will help shape future NHS guidelines, ensuring patients receive the best possible treatment while reducing unnecessary costs and discomfort.",[410,27],"Hip Fractures",[412,413,414,415],"Hip fracture","Blood clot","Aspirin","Low molecular weight heparin (LMWH)","2026-01-05",{"date":418,"type":35},"2026-01-06",{"date":420,"type":21},"2026-08-01",{"date":422,"type":21},"2028-04-30",{"name":424,"class":101},"Queen Mary University of London",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":433,"targetDuration":435,"studyType":268,"phases":4,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":453},"100616829","external-validation-of-the-clover-score-for-detecting-occult-cancer-in-venous-thromboembolism-patients-100616829","NCT07310693","External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients","External Validation of a Predictive Model for Occult Cancer Risk in Patients With Venous Thromboembolism Developed Using Machine Learning","CLOVER","Inclusion Criteria:\n\n* Age ≥18 years.\n* Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and\u002For pulmonary embolism).\n* Ability to provide written or electronic informed consent.\n\nExclusion Criteria:\n\n* Suspicion of cancer during the initial diagnostic evaluation for VTE.\n* Participation in another interventional study that may interfere with outcomes.\n* Inability or refusal to provide informed consent.",{"count":434,"type":21},500,"2 Years","This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.",[27,438],"Occult Cancer",[438,324,440,441,442,443],"Machine learning","Prediction model","External validation","CLOVER score","2025-12-20",{"date":446,"type":35},"2025-12-30",{"date":448,"type":35},"2025-12-01",{"date":450,"type":21},"2028-12-31",{"name":452,"class":101},"Infanta Leonor University Hospital",12,{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":268,"phases":4,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":205},"100615132","effects-of-genomic-profiles-on-thromboembolic-risk-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-100615132","NCT07288632","Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer","Inclusion Criteria:\n\n* • Patients aged 18 years or older,\n\n  * Cytological or histological confirmation of NSCLC,\n  * Locally advanced or metastatic disease (Stage III-IV),\n  * Patients starting a new anticancer treatment for locally advanced\u002Fmetastatic disease (first or further line of treatment),\n  * Testing for oncogenic (EGFR, KRAS, ALK, ROS1 and PD-1\u002FPD-L1) profile performed,\n  * Written informed consent\n\nExclusion Criteria:\n\n* • Patients received surgery or radiotherapy for lung cancer within the past 3 months before recruitment or chemotherapy within the past 1 months before recruitment,\n\n  * Patients with a history of VTE after cancer diagnosis or evidence of VTE events at enrollment\n  * Continuative use of anticoagulant drugs for any indication (atrial fibrillation or previous VTE)\n  * ECOG performance profile 3 or 4\n  * Life expectancy of less than 3 months",{"count":434,"type":21},"Multicenter, prospective observational study (15 Oncologic Centers, in Italy). The purpose of the study is to assess the thromboembolic potential in patients with oncogene-addicted and wild-type NSCLC. The primary aim of this project is to evaluate the association between oncogene mutations and levels of plasma parameters of the activated coagulation cascade as the plasma levels of TF, thrombin generation, IL 6, vWF, ADAMTS-13 activity, PAI-1, and soluble P-selectin in NSCLC patients. A total of 500 NSCLC patients with a diagnosis (cytologically or histologically confirmed) of locally advanced or metastatic disease will be enrolled in the study, with a ratio of 1:1 for oncogene addicted or wild-type group. The oncogene-addicted group (Group A): patients with at least one oncogene mutation (i.e., patients expressing EGFR mutations, KRAS mutation, ALK or ROS1 rearrangements); the wild type group (Group B): patients without oncogene mutations, categorized in 2 subgroups according to expression of PD1\u002FPD-L1 mutation or not. Patients will be followed up prospectively for 6 months or until death, VTE event, loss to follow-up, or voluntary consent withdrawal.\n\nThis study will evaluate the effects of EGFR, KRAS mutations and ALK\u002FROS 1 and PD-1\u002FPD-L1 rearrangements on the expression of TF and thrombin generation or the interaction between inflammation and endothelial or platelet and cancer cells, in patients with NSCLC. The study will also evaluate the potential correlation between VTE events and the expression of oncogene mutations in patients with NSCLC.\n\nThe results of this study could generate the hypothesis of including the genetic profile as variable for a risk-stratification tools and decision-making algorithms in NSCLC patients.",[27,463],"NSCLC (Advanced Non-small Cell Lung Cancer)",[465,466,467,468],"NSCLC","venous thromboembolism","genomic profile","activation of coagulation cascade","2025-12-03",{"date":152,"type":35},{"date":472,"type":35},"2024-02-09",{"date":474,"type":21},"2026-02-28",{"name":476,"class":101},"University Of Perugia",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":17,"minAge":485,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":493,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":504,"leadSponsor":506,"locationsCount":508},"100610521","phase-3-hip-fracture-surgery-arterial-and-venous-thrombotic-events-prevention-100610521","NCT07228663","Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial","HIPSTER-Pilot","Inclusion Criteria:\n\n* Age ≥45 years, received surgery for a hip fracture due to a low-energy mechanism, and myocardial injury (i.e., an elevated troponin measurement).\n\nExclusion Criteria:\n\n* Centers in which standard of care for VTE prophylaxis after hip fractures is ASA, alone or in combination with other drugs; patients with GFR \\\u003C15mL\u002Fmin; patients with drug interactions and conditions that prevent the use of the standard of care or intervention \\[Known allergy to the study drugs; pregnancy; an indication for anticoagulation, for dual antiplatelet therapy, for a P2Y12 inhibitor; already on rivaroxaban 2.5 mg twice daily + ASA before the fracture; bleeding diathesis that in the judgment of the investigator precludes the use of anticoagulant prophylaxis; history of significant hepatic disease (Child-Pugh B or C, see supplementary material) or any other condition that, in the judgment of the investigator, precludes the use of rivaroxaban; concomitant use of drugs that are strong inhibitors or strong inducers of P-glycoprotein (P-gp, e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \\[HIV\\]-protease inhibitors, such as ritonavir) and\u002For Cytochrome P450 3A4 (CYP3A4)\\]; expected requirement for major surgery post-arthroplasty within 90 days; women Persons of childbearing potential who are not abstinent or do not use appropriate contraception or are breast-feeding; unable or unwilling to provide consent; previous participation in the HIPSTER trial; participation in another anticoagulant or antiplatelet study.","45 Years",{"count":487,"type":21},100,[24],"A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.",[491,492,27],"Hip Fracture Surgery","Cardiovascular Prevention",[494,495,496,497,498,499],"rivaroxaban","acetylsalicylic acid","cardiovascular prevention","hip fracture surgery","myocardial injury","venous thromboembolism (VTE)","2025-11-13",{"date":502,"type":35},"2025-11-14",{"date":448,"type":21},{"date":505,"type":21},"2027-12-01",{"name":507,"class":101},"McMaster University",3,{"id":510,"slug":511,"hasResults":11,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":166,"minAge":18,"maxAge":485,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":518,"conditions":519,"keywords":522,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":540,"leadSponsor":542,"locationsCount":205},"100605859","informative-video-before-lmwh-postpartum---randomized-controlled-trial-100605859","NCT07168005","Informative Video Before LMWH Postpartum - Randomized Controlled Trial","Does an Informative Video Reduce Anxiety and Pain Before LMWH Treatment Postpartum? - A Randomized Controlled Trial","Inclusion Criteria:\n\nWomen 18-45 years, postpartum, indicated for LMWH, Hebrew-literate, gave consent\n\nExclusion Criteria:\n\nUse of LMWH pre-delivery, IUFD, pregnancy termination, language\u002Fcognitive barrier",{"count":125,"type":21},[80],"This single-center randomized controlled trial evaluates whether a short informative video can reduce anxiety and pain before the first postpartum administration of low molecular weight heparin (LMWH, Clexane). Eligible women will be randomized to receive either standard explanation alone or standard explanation plus a short educational video. The primary outcome is anxiety level assessed via the State-Trait Anxiety Inventory (STAI). Secondary outcomes include pain, satisfaction, and treatment adherence.",[27,520,521],"Postpartum Care","Anxiety",[353,523,524,525,526,527,521,528,529,530,531,532,520,533,534,535],"Venous Thromboembolism","VTE","LMWH","Low Molecular Weight Heparin","Clexane","Pain","Patient Education","Informative Video","State-Trait Anxiety Inventory","STAI","Women's Health","Obstetrics","Adherence","2025-09-03",{"date":538,"type":35},"2025-09-11",{"date":358,"type":21},{"date":541,"type":21},"2027-10-15",{"name":543,"class":339},"Wolfson Medical Center",{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":191,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":268,"phases":4,"briefSummary":553,"conditions":554,"keywords":557,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":231},"100572315","heat-shock-protein-47-in-thrombosis-100572315","NCT06731673","Heat Shock Protein 47 in Thrombosis","Heat Shock Protein 47: A Novel Biomarker of Thrombosis Risk","Inclusion Criteria:\n\n* 18 years of age or older\n* Informed consent\n\nVTE group:\n\n* Deep vein thrombosis confirmed on ultrasonography OR\n* Pulmonary embolism confirmed on computed tomography angiography (CTA)\n\nAMI group:\n\n* ST-segment elevation on electrocardiogram (ECG) AND\n* Culprit lesion(s) on coronary angiography\n\nStroke group:\n\n* Stroke confirmed on magnetic resonance imaging AND\n* Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND\n* Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical \\>1.5 cm in diameter\n\nHealthy group:\n\n\\- Healthy\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* no informed consent\n* Known haematological disorders\n* Active haematological malignancy\n* Severe renal insufficiency defined as eGFR \\\u003C15 or dialysis\n\nVTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT\n\nAMI\n\n* Coronary dissection\n* Takotsubo cardiomyopathy\n\nStroke\n\n\\- Stroke from other causes, e.g. findings pointing towards large vessel disease\n\nHealthy\n\n* Known acute or chronic disease\n* Prior VTE, AMI, stroke or other thromboembolic event",{"count":552,"type":21},340,"The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:\n\n1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers.\n2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up.\n3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event.\n\nParticipants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.",[27,555,556],"Acute Myocardial Infarction With ST Segment Elevation","Stroke (in Patients With Atrial Fibrillation)",[558,559,560,561,562,524,563,564],"HSP47","Heat Shock Protein 47","Biomarker","Novel biomarker","Trombosis","AMI","Stroke","2025-08-15",{"date":567,"type":35},"2025-08-21",{"date":569,"type":35},"2024-12-09",{"date":571,"type":21},"2027-08-31",{"name":573,"class":101},"University of Aarhus",{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":584,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":205},"100589759","phase-4-pulsed-electromagnetic-field-therapy-or-pneumatic-compression-vte-prophylaxis-100589759","NCT06958588","Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis","Pulsed Electromagnetic Field Therapy (PEMF) Compared to Conventional Mechanical Prophylaxis for Venous Thromboembolism Prophylaxis in Patients in the Intensive Care Unit (ICU)","SOPHIE","Inclusion Criteria:\n\n1. Patients \\> 18 years old in ICU\n2. PADUA score\\> 4 (medical patients) and\u002For Caprini score\\> 3 (surgical patients)\n3. Contraindication to pharmacological prophylaxis or indication to combined (pharmacological and mechanical VTE prophylaxis)\n\nExclusion Criteria:\n\n1. Patients \\\u003C 18 years old in ICU\n2. Unable to use mechanical prophylaxis due to trauma, burns, fracture, or problems in inferior members that prevent the use of mechanical prophylaxis\n3. Life expectations less than 24 hours",{"count":583,"type":21},50,[170],"Venous thromboembolism (VTE) is frequent in patients in the intensive care unit (ICU). Pharmacologic prophylaxis is sometimes contraindicated, and mechanical prophylaxis is used. The primary objective of the study is to compare Pulsed Electromagnetic Field Therapy (PEMF) with conventional mechanical prophylaxis for the prevention of VTE in patients in the ICU.",[27,587,523],"Intensive Care Medicine",[466,589,590,591,592],"Mechanical prophylaxis","Pulsed Electromagnetic Field Therapy (PEMF)","ICU","intensive care unit","2025-04-25",{"date":595,"type":35},"2025-05-06",{"date":597,"type":21},"2025-05-25",{"date":599,"type":21},"2026-03-20",{"name":601,"class":101},"Science Valley Research Institute",{"id":603,"slug":604,"hasResults":11,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":22,"phases":611,"briefSummary":613,"conditions":614,"keywords":616,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":625,"locationsCount":4},"100566982","phase-2-anti-xa-guided-dosing-of-low-molecular-weight-heparin-for-prevention-of-venous-thromboembolism-following-traumatic-injury-a-multicentre-pilot-randomized-trial-100566982","NCT06662253","Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial","PrOVE iT","Inclusion Criteria:\n\n* Patients 18 years of age or older admitted to a hospital ward or intensive care unit following a traumatic injury involving two or more body systems (head, chest, abdomen, pelvis, extremity) and meeting at least one of the following high-risk criteria previously identified in a recent systematic review (1): age ≥ 65, body mass index ≥ 30 kg\u002Fm2, injury severity score ≥ 16, pelvic injury with activity restrictions, lower extremity injury with activity restrictions, or surgery during the index hospitalization.\n\nTo be eligible, patients must be deemed appropriate for pharmacologic prophylaxis by the most responsible physician and randomized with the intention to receive prophylaxis within 48 hours of admission. Prior to randomization, there is no restriction on whether or not patients have previously received pharmacologic or mechanical prophylaxis.\n\nExclusion Criteria:\n\n1. Greater than 7 days since time of injury.\n2. Requirement for therapeutic anticoagulation or dual-antiplatelet therapy\n3. Unable or unwilling to receive pharmacologic prophylaxis within 48 hours of admission.\n4. History of allergic reaction or sensitivity to LMWH.\n5. Thrombocytopenia with platelets \\< 30.\n6. Expected discharge or transfer from hospital within 72 hours.",{"count":610,"type":21},150,[612,24],"PHASE2","This multicentre pilot trial will assess the feasibility of a full-scale, randomized trial to determine whether bloodwork guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients. Patients will receive either standard of care dosing or dosing with adjustments based on bloodwork to achieve a minimum therapeutic threshold.",[27,615],"Trauma Related Injuries",[617,466,618],"trauma","prophylaxis","2024-10-24",{"date":621,"type":35},"2024-10-28",{"date":623,"type":21},"2025-01",{"date":96,"type":21},{"name":626,"class":101},"Alexandre Tran",{"id":628,"slug":629,"hasResults":11,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":635,"enrollmentInfo":636,"targetDuration":4,"studyType":22,"phases":638,"briefSummary":639,"conditions":640,"keywords":644,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":4},"100562278","achilles-tendon-rupture---intervention-with-electrical-stimulation-100562278","NCT06601088","Achilles Tendon Rupture - Intervention With Electrical Stimulation","Acute Achilles Tendon Rupture - Intervention With Neuromuscular Electrical Stimulation","C-NMES-ATR","Inclusion Criteria:\n\n* Diagnosed with acute unilateral Achilles tendon rupture\n* Included within 10 days after injury.\n\nExclusion Criteria:\n\n* Inability to give consent to participate,\n* ongoing treatment with anticoagulants,\n* known allergy to contrast agents,\n* planned follow-up at another hospital,\n* inability to follow instructions,\n* known renal failure,\n* heart failure with pitting edema,\n* thrombophlebitis,\n* thromboembolic disease within the last 3 months,\n* previous surgery of the tendon,\n* known malignancy,\n* hemophilia,\n* pregnancy,\n* treatment with high doses of acetylsalicylic acid.","75 Years",{"count":637,"type":21},220,[80],"Acute Achilles tendon rupture (ATR) is an injury that is commonly associated with complications, such as blood clotting, muscle loss and tendon lengthening, all of which affect the long-term outcome and return to sports. These complication are related to the treatment of ATR with lower leg immobilization in a boot.\n\nThe investigators aim to demonstrate that an intervention with calf neuromuscular electrical stimulation (C-NMES) during leg immobilization after ATR can 1) reduce blood clots, 2) lower the degree of muscle loss, 3) decrease tendon lengthening and 4) improve long-term outcome.",[641,642,27,643],"Achilles Tendon Ruptures","Immobilization","Muscle Atrophy",[645,646],"neuromuscular electrical stimulation","duplex ultrasound","2024-09-15",{"date":649,"type":35},"2024-09-19",{"date":651,"type":21},"2025-01-15",{"date":653,"type":21},"2026-12-30",{"name":655,"class":101},"Karolinska University Hospital",{"id":657,"slug":658,"hasResults":11,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":268,"phases":4,"briefSummary":665,"conditions":666,"keywords":667,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":205},"100221153","vteval-project---prospective-cohort-studies-to-evaluate-and-improve-diagnostics-management-strategies-and-risk-stratification-in-vte-100221153","NCT02156401","VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE","VTEval Project - Three Observational, Prospective Cohort Studies Including Biobanking to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in Venous Thromboembolism","VTEval","Inclusion Criteria:\n\n* Age ≥18 years and Informed written consent\n* Clinical condition:\n\n  * Cohort 1: Clinical suspicion of acute PE (with or without DVT)\n  * Cohort 2: Clinical suspicion of acute DVT (without symptomatic PE)\n  * Cohort 3: Incidentally diagnosed VTE",{"count":20,"type":21},"Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality. The incidence of VTE increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed.\n\nVTEval Project includes three long-term prospective observational studies to evaluate and improve VTE diagnostics and management, treatment and outcome. The aims of the project include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. VTEval collects three large prospective cohorts of patients with suspected and incident VTE consisting of individuals with a clinical suspicion of acute PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental diagnosis of VTE).\n\nThe standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on VTE, thus providing the basis for both short- and long-term analysis.",[27,83,221],[324,323,668,669,670,671],"Pulmonary embolism","Cohort study\u002Fepidemiology","Outcome","Prognosis","2024-06-14",{"date":674,"type":35},"2024-06-17",{"date":676,"type":35},"2013-04",{"date":678,"type":21},"2030-07",{"name":680,"class":101},"Johannes Gutenberg University Mainz"]